Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Event Details

Repatha® (evolocumab) Cardiovascular Outcomes Trial (FOURIER) Detailed Results at ACC.17
Friday, March 17, 2017 9:00 a.m. ET  

Event Details
TitleRepatha® (evolocumab) Cardiovascular Outcomes Trial (FOURIER) Detailed Results at ACC.17
Date and TimeFriday, March 17, 2017 9:00 a.m. ET  

The Repatha® (evolocumab) Cardiovascular Outcomes Trial (FOURIER) results are being presented at the American College of Cardiology 66th Annual Scientific Session (ACC.17) by the TIMI Study Group, an academic research organization of Brigham & Women's Hospital and an affiliate of Harvard Medical School.

The webcast presentation and accompanying slides are provided here with the permission of the American College of Cardiology.  The views expressed in the presentation are the views of the presenters. 

This presentation has ended. An archive video is available for viewing.

Download the TIMI presentation slides below. The presentation slides are provided as part of TIMI’s oral presentation at ACC.17 and are qualified by the oral presentation.

TIMI Study Group presentation of Repatha® (evolocumab) Cardiovascular Outcomes Trial (FOURIER) results